Work

Low RPMB indicates better disease-free survival of adjuvant radiotherapy after radical surgery in thymoma.

Year: 2023

Type: article

Abstract: BACKGROUND: The current use of adjuvant radiotherapy in thymoma (THYM) following radical surgery is primarily based on clinical factors and is a subject of ongoing debate. METHODS: We developed a new biomarker, promotor methylation burden of Deoxyribonucleic acid repair genes (RPMB), to identify patients who may benefit from adjuvant radiotherapy after complete resection in THYM. RPMB quantitatively measures the promoter methylation level of Deoxyribonucleic acid (DNA) repair genes. RESULTS: = 0.028). CONCLUSIONS: Low RPMB may be a potential indicator to identify suitable patients who can benefit from adjuvant radiotherapy in THYM, sparing others from treatment toxicity.

Source: PubMed Central

Authors: Ning An, Li Cui, Xue Yang

Institutions: Affiliated Hospital of Qingdao University, Linyi People's Hospital

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, National Cancer Institute

Awards: G2139235618, G7155098242, G7933522964